A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Abroad (travel likely)RecruitingPHASE1
Conditions
Myelofibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope, Duarte, California, United States
City of Hope, Irvine, California, United States
University of Miami, Coral Gables, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Texas Oncology, Denison, Texas, United States
Texas Oncology, Tyler, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Study leads
Michelle Mudge-Riley, DO
Study Director
Geron Corporation